2′,3′-dideoxyinosine (ddl) and 2′,3′-dideoxythymidiene (d4T) have been reported to inhibit the multiplication of human immunodeficiency virus (HIV) in patients, ddl and d4T were administered subcutaneously to cynomolgus monkeys starting 8 h prior to inoculation with 10–50 infectious doses of simian immunodeficiency virus (SIVSM). ddl, at a daily dose of 3 × 3.6 mg kg−1 for 10 days significantly delayed the appearance of SIVSM p24/26 antigen. A significant delay in the appearance of SIVSM p24/26 antigen was also seen when using a daily dose of 3 × 1 mg kg −1 of d4T for 10 days. Neither ddl nor d4T prevented SIVSM infection despite administration prior to virus inoculation.
References
1.
AhluwaliaG.JohnsonM.AFridlandA.CooneyD.A.BroderS., and JohnsD.G. (1988) Cellular pharmacology of the anti-HIV agent 2′,3′-dideoxyadenosine. Proc Am Assoc Cancer Res29: 349. Abstract.
2.
ButlerK.M.HussonR.N.BalisF.M.BrouwersP.EddyJ.El-AminD.GressJ.HawkinsM.JarosinskiP.MossH.PoplackD.SantacroceS.VenzonD.WienerL.WoltersP., and PizzoP.A. (1991) Dideoxyinosine in children with symptomatic human immunodeficiency virus infection. N Engl J Med324: 137–144.
3.
CooleyT.P.KunchesL.M.SaundersC.A.PerkinsC.J.KelleyS.L.McLarenC.McCaffreyR.P., and LiebmanH.A. (1990a) Treatment of AIDS and AIDS-related complex with 2′,3′-dideoxyinosine given once daily. Rev Inf Dis12, suppl 5: 552–560.
4.
CooleyT.P.KunchesL.M.SaundersC.A.RitterJ.K.PerkinsC.J.McLarenC.McCaffreyR.P., and LiebmanH.A. (1990b) Once-daily administration of 2′,3′-dideoxyinosine (ddl) in patients with the acquired immunodeficiency syndrome or AIDS-related complex. N Engl J Med322: 1340–1345.
5.
DolinR.LambertJ.S.MorseG.D.ReichmanR.C.PlankC.S.ReidJ.KnuppC.McLarenC., and PettinelliC. (1990) 2′,3′-Dideoxyinosine in patients with AIDS or AIDS-related complex. Rev Inf Dis12, suppl 5: 540–551.
6.
FultzP.N.McClureH.M.AnderssonD.C.SwensonR.B.AnandR., and SrinivasanA. (1986) Isolation of a T-lymphotropic retrovirus from naturally infected sooty mangabey monkeys (Cercocebus atys). Proc Natl Acad Sci USA83: 5286–5290.
7.
HabteyesusA.NordenskjöldA.BohmanC., and ErikssonS. (1991) Deoxynucleoside phosphorylating enzymes in monkey and human tissues show great similarities, while mouse deoxycytidine kinase has a different substrate specificity. Biochem Pharmacol.42: 1829–1836.
8.
HartmanN.R.YarchoanR.PludaJ.M.ThomasR.V.MarczykK.S.BroderS., and JohnsD.G. (1990) Pharmacokinetics of 2′,3′-dideoxyadenosine and 2′,3′-dideoxyinosine in patients with severe human immunodeficiency virus infection. Clin Pharmacol Ther47: 647–654.
9.
HoH.-S., and HitchcockM.J.M. (1989) Cellular pharmacology of 2′,3′-dideoxy-2′,3′-didehydrothymidine, a nucleoside analog active against human immunodeficiency virus. Antimicrob Agents Chemother33: 844–849.
10.
LambertJ.S.SeidlinM.ReichmanR.C.PlankC.S.LavertyM.MorseG.D.KnuppC.McLarenC.PettinelliC.ValentineF.T., and DolinR. (1990) 2′,3′-Dideoxyinosine (ddl) in patients with the acquired immunodeficiency syndrome or AIDS-related complex. N Engl J Med322: 133–1340.
11.
LarderB.A.ChesebroB., and RichmanD.D. (1990) Susceptibilities of Zidovudine-susceptible and -resistant human immunodeficiency virus isolates to antiviral agents determined by using a quantitative plaque reduction assay. Antimicrob Agents Chemother34: 436–441.
12.
Ljungdahl-StåhleE.TrojnarJ.ÖbergB., and WahrenB. (1991) Early appearance of simian immunodeficiency virus (SIV) antigen and antibodies as variables in evaluating antiviral drugs in macaques. J. Virol Meth, in press.
13.
LundgrenB.Ljungdahl-StåhleE.BöttigerD.BenthinR.HedströmK.-G.NorrbyE.PutkonenP.WahrenB., and ÖbergB. (1990) Acute infection of cynomolgus monkeys with Simian immunodeficiency virus (SIVSM) as a model to evaluate antiviral compounds. Effects of 3′-azido, 3′-deoxythymidine, foscarnet and 2′,3′-dideoxycytidine. Antivir Chem Chemother1: 299–306.
14.
LundgrenB.BöttigerD.Ljungdahl-StåhleE.NorrbyE.StåhleL.WahrenB., and ÖbergB. (1991) Antiviral effects of 3′-fluorothymidine and 3′-azidothymidine in cynomolgus monkeys infected with simian immunodeficiency virus. J AIDS4: 489–498.
15.
McClureH.M.AndersonD.C.FultzP.N.AnsariA.A.LockwoodE., and BrodieA. (1989) Spectrum of disease in macaque monkeys chronically infected with SIV/SM. Vet Immunol Immunopath21: 13–24.
16.
McClureH.M.AndersonD.C.AnsariA.A.FultzP.N.KlumppS.A., and SchinaziR.F. (1990) Nonhuman primate models for evaluation of AIDS therapy. In: AIDS, anti-HIV agents, therapies and vaccines. St. GeorgievV., and McGowanJ.J. (eds). Ann NY Acad Sci616: 287–298.
17.
McGowanJ.J.TomaszewskiJ.E.CradockJ.HothD.GrieshaberC.K.BroderS., and MitsuyaH. (1990) Overview of the preclinical development of an antiretroviral drug, 2′,3′-dideoxyinosine. Revint Dis12, suppl 5: 513–621.
18.
MansuriM.M.StarrettJ.E.GhazzouliI.HitchcockM.J.M.SterzyckiR.Z.BrankovanV.LinT.-S.AugustE.M.PrusoffW.H.SommadossiJ.P., and MartinJ.C. (1989) 1-(2,3-Dideoxy-β-D-glyceropent-2-enofuranosyl)thymidine (d4T). A highly potent and selective anti-HIV agent. J Med Chem32: 461–466.
PutkonenP.WarstedtK.ThorstenssonR.BenthinR.AlbertJ.LundgrenB.ÖbergB.NorrbyE., and BiberfeldG. (1989) Experimental infection of cynomolgus monkeys (Macaca fascicularis) with simian immunodeficiency virus. J AIDS2: 359–365.
21.
Qi***anM.FincoT.S.SwaglerA.R., and GalloJ.M. (1991) Pharmacokinetics of 2′,3′-Dideoxyinosine in Monkeys. Antimicrob Agents Chemother35: 1247–1249.
22.
RozencweigM.McLarenC.BeltangadyM.RitterJ.CanettaR.SchacterL.KelleyS.NicaiseC.SmaldoneL.DunkleL.BarbhaiyaR.KnuppC.CrossA.TsiancoM., and MartinR.R. (1990) Overview of phase I trials of 2′,3′-dideoxyinosine (ddl) conducted on adult patients. Rev Inf Dis12, suppl 5: 570–575.
23.
SchinaziR.F.BoudinotF.D.DoshiK.J., and McClureH.M. (1990) Pharmacokinetics of 3′-fluoro-3′-deoxythymidine and 3′-deoxy-2′,3′-didehydrothymidine in rhesus monkeys. Antimicrob Agents Chemother34: 1214–1219.
24.
SquiresK.E.WeissW.SacksH.HassettJ.GugliottiR., and MurrayH. (1990b) Phase I trial of 2′,3′-didehydro-3′-deoxythymidine (d4T) in patients with AIDS or ARC. CDC AIDS weekly 05/07/90, 14.
25.
TsaiC.-C.FollisK.E.YarnallM.DeaverL.E.BenvenisteR.E., and SagerP.R. (1990) In vitro screening for antiretroviral agents against simian immunodeficiency virus (SIV). Antiviral Research14, 87–98.
26.
ValentineF.T.SeidlinM.HochsterH.LavertyM. (1990) Phase I Study of 2′,3′-dideoxyinosine: Experience with 19 patients at New York University Medical Center. Rev Infect Dis12, suppl 5: 534–539.
27.
YarchoanR.MitsuyaH.PludaJ.M.MarczykK.S.ThomasR.V.HartmanN.R.BrouwersP.PernoC.-F.AllainJ.-P.JohnsD.G., and BroderS. (1990a) The National Cancer Institute phase I study of 2′,3′-dideoxyinosine administration in adults with AIDS or AIDS-related complex: Analysis of activity and toxicity profiles. Rev Infect Dis12, suppl 5: 522–533.
28.
YarchoanR.PludaJ.M.ThomasR.V.MitsuyaH.BrouwersP.WyvillK.M.HartmanN.JohnsD.G., and BroderS. (1990b) Long-term toxicity/activity profile of 2′,3′-dideoxyinosine in AIDS or AIDS-related complex. Lanceti: 526–529.
